CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Trubion Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Trubion Pharmaceuticals, Inc.
2401 4th Avenue
Suite 1050
Phone: (206) 838-0500p:206 838-0500 Seattle, WA  98121  United States Ticker: TRBNTRBN

This company was Merged or Acquired on 10/28/2010.
This company ceased filing statements with the SEC on 11/5/2010.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Trubion Pharmaceuticals, Inc. (Trubion) is a biopharmaceutical company creating a pipeline of protein therapeutic product candidates to treat autoimmune and inflammatory diseases, and cancer. The Company’s product development efforts are focused on three technologies: Small Modular Immunopharmaceutical (SMIP), protein therapeutics, SCORPION protein therapeutics, and TRU-ADhanCe potency enhancing technology for immunopharmaceuticals. As of December 31, 2009, the Company’s clinical-stage therapeutics target specific antigens on B cells, CD20 and CD37, and are designed using its custom drug assembly technology. Trubion lead product candidate, TRU-015, which the Company is developing with its partner, Pfizer Inc. (Pfizer), has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis (RA).
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201012/31/2009YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, Acting President, Principal Executive Officer StevenGillis 56 11/16/2009 1/1/2006
Chief Financial Officer, Vice President, Treasurer John A.Bencich 33 11/16/2009 11/16/2009
Chief Operating Officer, Senior Vice President Michelle G.Burris 44 11/16/2009 2/1/2006
8 additional Officers and Directors records available in full report.

Business Names
Business Name
TRBN
Trubion Pharmaceuticals Inc.
Trubion Pharmaceuticals, Inc
Trubion Pharmaceuticals, Inc
Trubion Pharmaceuticals, Inc.

General Information
Number of Employees: 73 (As of 12/31/2009)
Outstanding Shares: 20,421,294 (As of 7/31/2010)
Shareholders: 35
Stock Exchange: NASD
Federal Tax Id: 522385898
Fax Number: (206) 838-0503


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023